Prevalence of desloratadine poor metabolizer phenotype in healthy Jordanian males
作者： Nancy Hakooz , Isam I. Salem
DOI: 10.1002/BDD.1770
关键词: Endocrinology 、 Cmax 、 Desloratadine 、 Loratadine 、 Incidence (epidemiology) 、 Medicine 、 Desloratadine Oral Tablet 、 Pharmacokinetics 、 Poor metabolizer 、 Internal medicine 、 Plasma concentration
摘要: Purpose To study the prevalence of desloratadine slow metabolizer phenotype among a group healthy Jordanian male volunteers. Methods A total 62 volunteers were included in this study. A single 5 mg oral tablet was given and blood samples taken to determine 3-hydroxydesloratadine (3-OH-desloratadine) concentrations using specific liquid chromatography-mass spectrometric method (LC/MS/MS). The determination pharmacokinetic parameters all individuals determined by Kinetica® program version 4.1. Poor metabolizers or as having 3-OH-desloratadine exposure ratio lower than 10% half-life ≥ 50 h. Results Among who participated there only two labeled metabolizers, giving 3.2%. maximum plasma (Cmax) similar extensive groups but longer time (tmax) needed achieve concentration one metabolizer. Conclusion The incidence poor population studied is certain ethnic (e.g. Asian, Caucasians Hispanic); however, it other populations American Indians Black). Copyright © 2012 John Wiley & Sons, Ltd.
sci-hub.se 参考文章(19)
Lawrence DuBuske, Desloratadine for chronic idiopathic urticaria : A review of clinical efficacy American Journal of Clinical Dermatology. ,vol. 8, pp. 271- 283 ,(2007) , 10.2165/00128071-200708050-00002
Raif S. Geha, Eli O. Meltzer, Desloratadine: A new, nonsedating, oral antihistamine Journal of Allergy and Clinical Immunology. ,vol. 107, pp. 751- 762 ,(2001) , 10.1067/MAI.2001.114239
Melton Affrime, Christopher Banfield, Samir Gupta, Albert Cohen, Tanya Boutros, Mohan Thonoor, Mitchell Cayen, Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine. Clinical Pharmacokinectics. ,vol. 41, pp. 21- 28 ,(2002) , 10.2165/00003088-200241001-00004
Melton Affrime, Samir Gupta, Christopher Banfield, Albert Cohen, A pharmacokinetic profile of desloratadine in healthy adults, including elderly. Clinical Pharmacokinectics. ,vol. 41, pp. 13- 19 ,(2002) , 10.2165/00003088-200241001-00003
William E Berger, The Safety and Efficacy of Desloratadine for the Management of Allergic Disease Drug Safety. ,vol. 28, pp. 1101- 1118 ,(2005) , 10.2165/00002018-200528120-00005
John C Anthes, Helen Gilchrest, Christian Richard, Stephen Eckel, Dave Hesk, Robert E West, Shirley M Williams, Scott Greenfeder, Motasim Billah, William Kreutner, Robert W Egan, Biochemical characterization of desloratadine, a potent antagonist of the human histamine H1 receptor European Journal of Pharmacology. ,vol. 449, pp. 229- 237 ,(2002) , 10.1016/S0014-2999(02)02049-6
Christopher Banfield, Thomas Hunt, Larisa Reyderman, Paul Statkevich, Desmond Padhi, Melton Affrime, Lack of clinically relevant interaction between desloratadine and erythromycin. Clinical Pharmacokinectics. ,vol. 41, pp. 29- 35 ,(2002) , 10.2165/00003088-200241001-00005
Christopher Banfield, Samir Gupta, Mark Marino, Josephine Lim, Melton Affrime, Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clinical Pharmacokinectics. ,vol. 41, pp. 311- 318 ,(2002) , 10.2165/00003088-200241040-00004
Samir Gupta, Christopher Banfield, Melton Affrime, Thomas Marbury, Desmond Padhi, Paul Glue, Oral bioavailability of desloratadine is unaffected by food. Clinical Pharmacokinectics. ,vol. 41, pp. 7- 12 ,(2002) , 10.2165/00003088-200241001-00002
R. Ramanathan, L. Reyderman, A.-D. Su, N. Alvarez, S. K. Chowdhury, K. B. Alton, M. A. Wirth, R. P. Clement, P. Statkevich, J. E. Patrick, Disposition of desloratadine in healthy volunteers Xenobiotica. ,vol. 37, pp. 770- 787 ,(2007) , 10.1080/00498250701463325